YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Advanced Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a dual-action small molecule that directly activates soluble guanylyl cyclase (sGC) and inhibits hypoxia-inducible factor 1-alpha (HIF-1α) expression at the post-transcriptional level, with an IC₅₀ of 1.2 µM for hypoxia-induced HIF-1 transcriptional activity (APExBIO). YC-1 reduces tumor vascularization and suppresses genes downstream of HIF-1α in vivo, confirming its anti-angiogenic properties. The compound is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but insoluble in water, and is delivered as a crystalline solid with ≥98% purity. APExBIO supplies YC-1 for research use only, ensuring quality and reproducibility. YC-1 is not intended for diagnostic or clinical applications.

Biological Rationale

Hypoxia is a hallmark of solid tumors and drives malignant progression by stabilizing HIF-1α, which upregulates genes involved in angiogenesis, metabolism, and survival. Inhibition of HIF-1α disrupts tumor adaptation to hypoxia and impairs vascularization. Soluble guanylyl cyclase (sGC) is a central enzyme in the cGMP signaling pathway, regulating vascular tone, platelet aggregation, and cellular responses to nitric oxide (NO). YC-1 was originally developed as a HIF-1α inhibitor and later found to activate sGC independently of NO, providing dual leverage over hypoxia signaling and vascular homeostasis (Related Article). This article elaborates on recent findings and clarifies mechanistic distinctions beyond earlier site coverage.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 binds directly to sGC, inducing a conformational change that increases cGMP synthesis even in the absence of NO. This elevates intracellular cGMP levels, resulting in vasodilation and inhibition of platelet aggregation. Independently, YC-1 suppresses HIF-1α protein accumulation during hypoxic stress by inhibiting its translation or promoting degradation, thereby blocking HIF-1-dependent transcription. Notably, the anti-cancer effects of YC-1 are primarily attributed to HIF-1α pathway inhibition rather than sGC activation (Related Article). This dual activity enables selective targeting of tumor microenvironment and hypoxia-adaptive mechanisms.

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC₅₀ of 1.2 µM in vitro (APExBIO).
• In preclinical models, YC-1 treatment yields tumors that are smaller and less vascularized compared to controls (https://hif-1.com).
• YC-1 activates sGC and increases cGMP in vascular smooth muscle, leading to reduced vascular contraction and platelet aggregation (Elama et al., 2022).
• YC-1 is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), enabling high-concentration stock solutions for experimental use (APExBIO).
• Purity is routinely verified at ≥98% by APExBIO, supporting reproducible research outcomes (APExBIO).

Applications, Limits & Misconceptions

YC-1 is applied extensively in cancer biology, hypoxia signaling, and vascular research. It is a reference compound for dissecting the cGMP signaling and oxygen-sensing pathways. YC-1 is also used to evaluate the interplay between HIF-1α inhibition and angiogenesis in preclinical models (Related Article). This article updates mechanistic insights on mitochondrial quality control and tumor microenvironment modulation, extending previous reviews.

Common Pitfalls or Misconceptions

• YC-1 is not selective for sGC activation in the context of hypoxia; its primary anti-cancer effect arises from HIF-1α inhibition, not cGMP elevation.
• YC-1 is not water-soluble; attempts to use aqueous buffers will result in precipitation and unreliable dosing.
• Long-term storage of YC-1 solutions can lead to degradation; solutions should be prepared fresh and used promptly (APExBIO).
• YC-1 is not approved for clinical or diagnostic applications and is strictly for research use only.
• YC-1 should not be used as a direct substitute for PDE5 inhibitors such as vardenafil; it acts via distinct mechanisms (Elama et al., 2022).

Workflow Integration & Parameters

YC-1 is supplied as a crystalline solid (molecular weight 304.34 g/mol) and should be stored at room temperature in a desiccated environment. For in vitro use, stock solutions can be prepared at ≥30.4 mg/mL in DMSO or ≥16.2 mg/mL in ethanol and diluted into the desired medium immediately prior to use. YC-1 is incompatible with aqueous solvents due to insolubility. For in vivo studies, formulation strategies may require emulsifiers or co-solvents to ensure bioavailability. Researchers are advised to avoid repeated freeze-thaw cycles and to verify compound purity by HPLC or MS when reproducibility is critical. For detailed integration guidance and application data, refer to the YC-1 product page and explore the in-depth guide which provides advanced workflow strategies not covered here.

Conclusion & Outlook

YC-1 (B7641, APExBIO) is a validated research tool for modulating the cGMP and hypoxia pathways in cancer, vascular, and apoptosis research. Its combined sGC activation and HIF-1α inhibition profile has enabled mechanistic advances in tumor biology and preclinical modeling. As hypoxia signaling remains a therapeutic frontier, YC-1 continues to serve as a benchmark for biochemical, pharmacological, and translational studies. For future directions, combinatorial approaches leveraging YC-1 with other pathway modulators are under active investigation.